Explore
Validate
Learn24046-1-AP
antibody from Proteintech Group
Targeting: ZDHHC9
CGI-89, CXorf11, DHHC9, ZDHHC10, ZNF379, ZNF380
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 24046-1-AP - Provider product page
- Provider
- Proteintech Group
- Product name
- ZDHHC9 antibody
- Antibody type
- Polyclonal
- Description
- ZDHHC9 antibody (Cat. #24046-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse and has been validated for the following applications: IF, IHC, WB,ELISA.
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references ZDHHC9 palmitoylates LAMTOR1 to promote renal cell carcinoma malignant progression.
ZDHHC9 promotes osteosarcoma progression via KRAS-associated enhancement of the RAS/MAPK signaling pathway.
ZDHHC9-mediated CD38 palmitoylation stabilizes CD38 expression and promotes pancreatic cancer growth.
Multifunctional Copper-Phenolic Nanopills Achieve Comprehensive Polyamines Depletion to Provoke Enhanced Pyroptosis and Cuproptosis for Cancer Immunotherapy.
Palmitoylation alters LDHA activity and pancreatic cancer response to chemotherapy.
ZDHHC9: a promising therapeutic target for triple-negative breast cancer through immune modulation and immune checkpoint blockade resistance.
Liu B, Hou T, Liu X, Liu L, Ma Z, Zhang Y
Cell death & disease 2026 Mar 19;17(1)
Cell death & disease 2026 Mar 19;17(1)
ZDHHC9 promotes osteosarcoma progression via KRAS-associated enhancement of the RAS/MAPK signaling pathway.
Li Z, Li J, Wu Y, Luo Y, Zheng J, Shi J
Scientific reports 2025 Oct 14;15(1):35780
Scientific reports 2025 Oct 14;15(1):35780
ZDHHC9-mediated CD38 palmitoylation stabilizes CD38 expression and promotes pancreatic cancer growth.
Guo H, Lin Z, Zhang D, Qin Q, Li Z, Yin Y, Chen J, Guo W
Communications biology 2025 Mar 22;8(1):477
Communications biology 2025 Mar 22;8(1):477
Multifunctional Copper-Phenolic Nanopills Achieve Comprehensive Polyamines Depletion to Provoke Enhanced Pyroptosis and Cuproptosis for Cancer Immunotherapy.
Zhu G, Xie Y, Wang J, Wang M, Qian Y, Sun Q, Dai Y, Li C
Advanced materials (Deerfield Beach, Fla.) 2024 Nov;36(45):e2409066
Advanced materials (Deerfield Beach, Fla.) 2024 Nov;36(45):e2409066
Palmitoylation alters LDHA activity and pancreatic cancer response to chemotherapy.
Chen L, Xing X, Zhu Y, Chen Y, Pei H, Song Q, Li J, Zhang P
Cancer letters 2024 Apr 10;587:216696
Cancer letters 2024 Apr 10;587:216696
ZDHHC9: a promising therapeutic target for triple-negative breast cancer through immune modulation and immune checkpoint blockade resistance.
Xu C, Xie Y, Xie P, Li J, Tong Z, Yang Y
Discover oncology 2023 Oct 24;14(1):191
Discover oncology 2023 Oct 24;14(1):191
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- SH-SY5Y cells were subjected to SDS PAGE followed by western blot with 24046-1-AP( ZDHHC9 Antibody) at dilution of 1:300
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The ZDHHC9 antibody from Proteintech is a rabbit polyclonal antibody to a fusion protein of human ZDHHC9. This antibody recognizes human, mouse antigen. The ZDHHC9 antibody has been validated for the following applications: ELISA, WB, IHC analysis.
